The Food and Drug Administration (FDA, the Agency, or we) is announcing a public workshop regarding development of rabies monoclonal antibody products to be used in conjunction with licensed rabies vaccine as part of a rabies post-exposure prophylaxis (PEP) regimen. This public workshop is intended to provide information for, and gain perspective from, health care providers, other U.S. Government Agencies, academic experts, industry, and other stakeholders on various aspects of development efforts pertaining to animal models, laboratory assays, and clinical trials.
Document
Developing Rabies Monoclonal Antibody Products as a Component of Rabies Post-Exposure Prophylaxis; Public Workshop; Request for Comments
The Food and Drug Administration (FDA, the Agency, or we) is announcing a public workshop regarding development of rabies monoclonal antibody products to be used in conjunction ...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
82 FR 26494
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Developing Rabies Monoclonal Antibody Products as a Component of Rabies Post-Exposure Prophylaxis; Public Workshop; Request for Comments,” thefederalregister.org (June 7, 2017), https://thefederalregister.org/documents/2017-11820/developing-rabies-monoclonal-antibody-products-as-a-component-of-rabies-post-exposure-prophylaxis-public-workshop-reques.